PYPD - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the PolyPid First Quarter 2022 Conference Call. At this time, participants are in a listen-only mode.

As a reminder, this call is recorded. And I would now like to – introduce our host for today’s conference, Bob Yedid from LifeSci Advisors. Mr. begin. may you Yedid,

Bob Yedid

for PolyPid’s all Conference Quarter Call. participating you First in XXXX Thank

the be today, website, and today Executive XXst, me PolyPid’s release the section make ended Warshavsky, call meaning March call, Joining XXXX. on I’d company’s is Officer Operating of laws. will released of and Securities Czaczkes in for financial Executive months of the for Chief Officer Operations. Officer; Akselbrad, Amir this company press Vice Financial the The of remind three the forward-looking President to Investors Earlier Chief available the the US PolyPid; on Ori the you www.polypid.com. the Dikla like copy Chief Federal statements that Weisberg, within will results management

on timing management loan provides results pipeline, options second tranches from and for the statements discusses when release expected its the For the making Capital broadens third the appointments, capital, potential financing access recent their agreement forward-looking the the it and loan, trials, executive the a expected expected of example, the it the company’s is timing, with how significant basis recruitment drawdown interim Kreos data benefits of for the conditions of the analysis, non-dilutive implications. and and additional to company’s

market XXXX. into the conferences and fund operations D-PLEXXXX In its cash sufficiency quarter addition, company’s D-PLEXXXX, of opportunity potential additional OncoPLEX, and and forward-looking US for of benefits of to statements include and market addressable future preparations publications presentations D-PLEXXXX, and company’s commercialization the and products, of the ongoing use company’s important for scientific prelaunch activities, pre-commercialization partners, potential the future second the

time subject uncertainties, control, our which numerous in to beyond to SEC described risks many Forward-looking our of from filings. and time are statements including the are risks

limitation, not and to XXXX. be contains the projections by differ place from could differ. Accordingly, projections. actual those risks uncertainties events the on will Investors should or remarks, Our because you you call factors broadcast management of actual Form These from With materially statements, to without except pleasure over financial required to on to as I Weisberg, PolyPid including, SEC, these review statements of this live Amir? the specific turn update Amir differ the the any material to slides may or statements. or revise of which cause company’s the information, results may speaks the with XXth, the call only can disclaims prepared in results those described my obligation, events – CEO. intention team any identifies or completion that investors.polypid.com. at encourage of statements. section future undue XX-F, call copy law, as company’s the whether to found company’s reliance time-sensitive forward-looking or those of new A the it’s otherwise. filings This involve forward-looking materially cause information describe results under May or materially website events review the which today, conference

Amir Weisberg

welcome On our our PolyPid, XXXX at Bob. to of behalf call. to would you, like Thank earnings team quarter everyone I first

financially. to a colleagues to over Board will allowing me which the years. accomplish work am allow my I like operationally for years. hard us in a the opportunity serve this during also for of at all development over confidence as CEO shareholders call would XX to PolyPid clinically, much their is commitment strength now position grateful and this and stage, of PolyPid final and As support PolyPid and take thank I earnings of their my CEO, to be this for the to conference as our

company like Xst. current our Phase years with company joining As will time July its into become to commercialization, phase as effective is key appointment CEO, near well-deserved next guiding objectives. are again, which X Therefore, on the I Dikla lead it and the ago, PolyPid towards once her Dikla Since there a congrats our would potential growth. of has to trial, X advance to we been Dikla

the with shareholders SHIELD forward development review I the trial, Dikla including the along a XXX candidate, shareholder, of patients provide on to interim treatment is a With a our fully to and the analyzed once OncoPLEX continuous detailed of will I of results. financial turn As call, recommendation for DMC discussion our promising our upcoming other milestones solid of and product on the this on pipeline to tumors. our a to look call that, I now data update, over key

Following this, for your call she will questions. Dikla? open the

Dikla Czaczkes Akselbrad

all thank of call. Amir, you leadership you, and thank On joining for for the your past us Amir team, the steadfast the you, on entire Thank PolyPid XX over years. behalf

as invaluable Your have me prepared last upcoming guidance the over together to has months. we been CEO the several transition for

begin will of a brief status I that, update pipeline. on the With our please. providing slide, by Next

soft Israel. the extremely patients First, we Phase have prevention remain infection approximately rate the XX into enrolled D-PLEXXXX study X with States, of enrollment in site in surgical SSI. for United I, or SHIELD tissue abdominal evaluating XXX of the across study now our Europe about centers and pleased We

in to addition that recall SHIELD agreed Importantly, of analysis announcement, from our an you will unblinded request interim the FDA PolyPid’s I. the first for quarter

the efficacy size is analysis exceed request published early the during and objectives of expected to conducted analysis allow to stop results on The study pandemic. occur can based clinical trial is futility, for if and due sample follow-up for interim recently impact XX-days guidance the for trial reassessment. their pharmaceutical companies will complete to the or meeting shortly, SSI XXX ongoing the very the on trials FDA’s efficacy, statistical to An occur early rate stopping Our for concluded, on enrollment patients was which the expectations. COVID-XX address once

the the define NDA our more enrollment submission. targeted As to for we said interim opportunity our timeline analysis and patient this for precisely on the last range exceptional for study I call, an PolyPid is SHIELD

As patients XXX enrolled the in I was early into XXXX. SHIELD March a reminder,

slide, please. Next

of Conference remind Before that last clinical I building efficacy Phase Infection trial for on key focus was move promising SAGES peer-reviewed clinical that data from product candidate end, Society the we the throughout our significant safety like medical support of call this on would publication important a our and XXXX XXXX you to one the development recently value this and I on the discussed the positive of Annual To and D-PLEXXXX both of Surgical X for meeting. at XXXX on and at presented Meeting. presentation from we program priorities data evidence D-PLEXXXX,

PolyPid’s pre-commercialization activities give strengthen function, US. to and some the readiness our and enhance partnership in continue for to market our clinical discuss financial on commercial D-PLEXXXX, we Ori? development potential ongoing preparation color and opportunities our Before Ori will

Ori Warshavsky

Thank you, Dikla.

Next just slide, industry is please. the on over There based open surgeries. the year colorectal on soft for approximately abdominal In both surgeries source of X.X procedures, leading data. D-PLEXXXX comprised million believe invasive and annually, tissue appendectomy and million surgeries are US, hernia IQVIA repair, prescription procedure per we total addressable XX the market principally data, and minimally

related a Other in surgeries high-risk opportunity and an joint additional gynecology that for believe sternotomies, in other procedures. have relevant the million principally include high replacements of D-PLEXXXX which hysterectomies D-PLEXXXX and also procedures, surgeries, X.X vascular and abdominal an rate there urology, or surgeries. either including use We is SSI

for we activities, with to the Moreover, suite pricing per we Exparel of reimbursement was Zynrelef. go-to-market additional when D-PLEXXXX market healthcare plan, our advancing journey and line as out-patient and in a surgeon research an which our additional and to more which launch. of pricing of tactical examined rapid would part As From standpoint, in we execution for levers, settings drug surgery uptake $XXX prelaunch includes the by local our defining therapies and range tested drivers diligence differentiation vial such are for analyze in qualify value used $XXX requirements in to facilitate in-patient in used other are our the patient facilities. doing plan

area, in conferences. presentations as making of opinion scientific publications at also are onboarding for a well additional and the significant medical number affairs key important planning leaders including as We efforts

as Finally, established sales a number and And on Dikla. surgeon front, I with Dikla? in team. hand our the partners presence development that, US business established the the with with focused with as with continue them call back the of hospitals, will ex-US discussions potential to surgery well we for companies over

Dikla Czaczkes Akselbrad

Ori. Thank you,

please. slide, Next

has Her company operations will Clinical and continue XXXX and supply and sterile Research with engineering, of to EVP positive management on approval of quality impact Clinical We clinical will and Affairs to XXXX and prerequisite, the lead our expertise supply has His appointment an and strengthen and Regulatory heading meaningfully Operations contribution development since Dalit and Evgeny will – including recognition Regulatory President, Regulatory new operational Executive our Hazan with roles management logistics Vice enhance extended important role in pharmaceutical for have Dalit and of Evgeny PolyPid, her believe Dalit FDA manufacturing. of as operations initiatives. June technical is our served manufacturing, chain, We been of and Evgeny team responsibility. technical R&D affairs Research increasing new recent Development and optimization, since the Vice Affairs. PolyPid. the affairs. company’s Development span PolyPid’s President, and as promotion Senior Valdman to EVP, the as chain the

strengthens the last unique financing of balance made term our three broadens the loan quarter. for have comprised an facility. $X.X provide were well recently and pleased sheet, is D-PLEXXXX million agreement $X.X to please. This over technology in ability of million, slide, non-dilutive obtain a facility on Next platform. loan The advancement perspective respectively. We million with options basis our the and commercial significant to us invest progress future our to we access of which up excellent From capital, in as tranches non-dilutive secured additional amount as $XX to our of fund million, PLEX $XX capabilities

facility tranche sold of of unblinded approximately of as Also, of the our analysis of The our XXXX, drawn and at-the-market in into second Kreos available million $XX April by from first was results million our relates positive XXXX. potentially XXXX, of ordinary of subject the the existing runway million $X.X quarter can the will any Capital action, SHIELD third planned agreement loan be interim $X with shares this first the to we positive be $X.X combine the year. of second are made tranche ATM. Drawdown SHIELD This the I of to met. trial Drawdown end results I. million the quarter cash during the worth subject with obtaining extended sheet, balance other second it be or line to third from tranche and conditions from top or will of final if available tranche

$XX of million March of XXst, Kreos XXXX. was $XX.X cash, of April the excluding had loan, first XXXX, which As of deposits in company short-term and million, tranche drawn equivalents the cash

Next slide, please.

period to million primarily compared turn income the statement. XXst, March our $X.X XXXX, months to XXXX. expenses increase ended and expenses Research in let’s R&D same $X three-month Now of three development resulted for million the The from soft the the in trial development clinical the increased costs X were Phase expedited I for and surgery. recruitment and abdominal the of [technical expenses Marketing ongoing difficulty] business related in XXXX first to activities SHIELD quarter in were tissue

Operator

[Technical please. difficulty] moment, one Just

Ori Warshavsky

Hi, it. a looks or have problem, technical minutes fix we to give everyone. just two more so us It like one

Dikla Czaczkes Akselbrad

slightly period. difficulty] the million year $X.X recorded higher [technical prior than in the

recruitment strong first of quarter prior a clinical a as was This $X.X rate year the loss period. of compared company million had Phase to driven the million the primarily in trial. patient XXXX, SHIELD by I X For the in of $XX.X

call will open now your to questions. the Operator? We

Operator

you. Thank

now from [Operator from Barclays. Prasad And of Instructions] will the line ahead. the Please comes question the go Balaji session. We question-and-answer begin next

Balaji Prasad

Hi, good morning.

Just me. couple from

the excuse And of I extension this – how out-patient use the be his see sufficient would trial for that, current for remarks. an more you me, in for about think key the for curious could US if setting? Ori out was I out – an in are will readouts are setting D-PLEX? how not, looking out-patient potential probably conversations case insights also maybe the called in offer you approval you are Or – your in demand Ori, Firstly, the some And called an what evolving requirements from a Thanks. partners? Secondly, from requirements partnership into what for partners? maybe development perspective?

Ori Warshavsky

I’ll – Okay,

Dikla Czaczkes Akselbrad

first would Take – like I’ll you ahead. Ori, to go part. first the –

Ori Warshavsky

Dikla next the first one one. you, take Yes, and Balaji. Thank the I’ll take

looking we done are So on hospital surgeries piece, within out-patient, are out-patient the that right. the at

but it’s most the surgeries, stage, and of surgeries – These not ambulatory them, And these of at it’s done standalone that out-patient So at most this are centers. of piece. least an not all become within, XX-hour call patients an not piece let’s it, the them before surgery. in-patient in-patient are within have

in-patient, smaller repairs, done the They they question a but ones, reimbursement. question the So ones within more some still for a a invasive minimally are are the more are of will hernia of same hospital, the It’s by It’s major be out-patient. of ones of question of done the considered of open surgeons. some still and with reimbursement. risk example,

it’s talking the from SSI, exists. open is an From a if risk about decide a patient you surgery and as different higher-risk BMI an between there doing are here. more more risk. invasive, patient where still on still a will And an and risk high in-patient a So a reminder, The or doctor it’s of product to risk the quicker the prevention the the maybe whether know decide surgery but we the minimally doctor will older discharge surgery. of patient, a healthy patient versus a is

it, a, a in whether prevent into be there’s procedure in on out-patient and out. insurance know – looking of or is we payment try of and in-patient terms that will pass-through call infection, an There the insurance code something the of getting this versus an are regardless let’s out-patient, for you a for So it’s to question payment.

Dikla Czaczkes Akselbrad

as for Ori. you, discussions that we And the Thank the discussions, and regarding second your have. question partner

engaged in US and multiple US. in – we actively out medical – both So device in medical active of companies, device are with and the pharmaceuticals

level We are the with discussions. happy of

the say accelerated this there’s much actively once stage We that have interim at that not could with beside those engaged expect happy quite will are discussion. and we And the that we data. be we

Balaji Prasad

Thanks, Good Dikla. luck.

Dikla Czaczkes Akselbrad

morning. Thank Thank Good Balaji. you, you.

Operator

you. Thank

Next Please question from comes from Raymond go Wilbur the line of Elliot James. ahead.

Michael Parolari

Parolari Hi, on Michael guys. Elliot. Good for morning. This actually is

just NDA? data that before from speak think one the me, interim input FDA you process? the see Do Or largely So of efficacy a the expect in the to for positive you first second D-PLEX. readout then, And be itself analysis question guys assuming from further me. submission to submission would do able from for

if but on You the I apologies missed just touched have or might this you. Thank process D-PLEX? comments, IND on prepared in any update it,

Dikla Czaczkes Akselbrad

Sure, sure. morning. Good

think breakthrough do We opportunity with expect for of aspects a that Phase is next discuss X there’s FDA be an meet no end on submit the XXXX and meeting. labeling. – we that open add FDA to of the some this we especially to accepted sure be designation of an for on the later an to So what NDA information. and on well, the discussion we therapy rolling this submission could any need basis to could commercialization the and during This have, with us stage broadening – also an make a opening

FDA So we the line do after meet to the expect top results.

very there. pleased we the are for As program, OncoPLEX are with we where

the Of to that conference. pre-IND at meeting expect We be a X course, ago. we met large compared data it’s and priority few data. we’ve for program, FDA and published a Phase less some months will of to additional this I younger it’s XXX able publish Phase a supporting X, but this patient nice stage a

We with year. are as well protocol be the expect platform able product here we’ll the to as the around of companies update starting you end more And itself. discussions and on pharma also specific the the towards indication and timelines I

Michael Parolari

congrats, And best retirement. Got transition. Amir And CEO the of it, with helpful. that’s you. luck Thank the for

Dikla Czaczkes Akselbrad

Thank you.

Amir Weisberg

Thank you.

Dikla Czaczkes Akselbrad

both from you of Thank us.

Operator

Thank you.

of ahead. question Gary from from comes Nachman Markets. Please line Capital Next the go BMO

Gary Nachman

Hi, Congrats on the good morning. progress.

statistical interim the order then it And expected I, does mean if for in threshold you SHIELD need FDA take better to you how stop take? it that So analysis can more What And early? number regarding the what analysis? What’s efficacy unblinded maximum would you long agree on for than the that? a add? you will that? did on the what’s with hit And patients,

Dikla Czaczkes Akselbrad

Hi. Good morning, Gary.

of this So excuse three them. And missed thank there for me all any, were if you point. of please, I

So efficacy. does in it what terms mean better expected than of

clinical infection. in all – trials that XX% of than know at in we of more shown our XX% of them most have in all you So least today, reduction

– this will we is not can of disclose – XX% parameter what do an hoping So it’s this this see overwhelming that that the we can stage. are jeopardize at But to results. allow I overwhelming us to on not will than is that reason we better somewhere, do and the the blinding terms for in what be is that way.

annual quite Of that we specific is for more course, the that can is as – we And we’ve that, as what unblinded, can we our statistical patients, is sample cannot minimal be protocol the we question last could and are maximum this is when draft. This show report, this But recruiting this and overall. a something a under size we was the regards With be X,XXX everything that the in adjustment was statistical. indicated that. this long foresee could the as after, about maximum amazing hit. go patients than to

I overall But of think particular, that X.X% down go in X.X%. was that in you let on back instead we to me went something X%, more but it to regard. or the

Gary Nachman

then especially comfortable ability up have sites to sites also, and enrolled the And you patients. you to let’s considering you take? the dynamics XXX that And X,XXX are go at with to all would say, the their how have control measure these if quality with the the that Okay. How long accurately, COVID? endpoint XX

Dikla Czaczkes Akselbrad

Sure.

to XX question, with do as And about start COVID, to active come XX can second it some of that to quarter. see, a the physicians recruiting very have it’s and two to per to grew to centers. because – are part we graph we due time took rate nice have patients. you XXX two quarters as along And recruitment – here, go the of patients this well to for process we know for to how slide the that centers. We it, it it to the about see part we XXX had But I’ll investors see. So now and we get now this added quarters, constantly and of the to XXX we almost year call XXX

the So is adjudication need. we each also case, we that we the cases we for have committee that had are endpoint. is the that primary the time have that. for which Those infection processes what reviewing the to build privilege measured are And

analyzed patients being XXX not that for the interim influenced are now endpoint. So are that whole primary a it’s that one the

So we’re comfortable. very

a good trial here years clinical our bringing department, experience in medication. have in really small trial large team type in very We of of and in different and

So we about? comfortable And with was that. me part the are remind what second

Gary Nachman

COVID No, just in with quality just site control Yeah. general. the and at the just

Dikla Czaczkes Akselbrad

Yeah.

very we’re last tell for problem So months, see of now, do that. not you that. terms happy six in for with – now can And not recruitment, that the see we we I any do with the

what well it asking I will think – you of go have if in mean we to were the also what terms maximum, to timeline.

rate you months So math do patients XXX at to we additional expect, again, few XXX very of recruitment. of the could is the easily

Gary Nachman

Yeah.

question. Now, that I answered that you assume

lastly, purposes, some SHIELD for more was of maybe SHIELD put what’s study? any important fact the invasive I II Ori, that’s that So status minimally the does how procedures. been about, helpful. And just I? then including just until is you the that you of just completion that just And talked just for numbers that you know that of patients Have in guess, SHIELD hold enrolling on II? commercial

need data much to of some that Thanks. would talking So, about? you’re the targets you that hit how

Dikla Czaczkes Akselbrad

the And on have we will SHIELD previous put we recruited we activity X if with from XXX we currently that following sufficient. over we quarter, need you therapy plan yes, reduced that did remember, patients. the road it results approval. started the because, is FDA of in already terms a as X X in reported will the Phase for the understanding agreed I, Phase we the So breakthrough II, SHIELD until designation, And X

of parameter XXX the positive I, basis we not patients. data of of necessarily change will like but, So, will II, compound on SHIELD the of minimally from it, we the not some course, of on to course, additional invasive need SHIELD strategically

is this of Ori, So, the the invasive? the relate it to plan, aspect and and with of be be the minimally could FDA. the want part discussions reduced, this will you to

Ori Warshavsky

Gary. Yes hi, so –

high-risk settings open expect full-blown SHIELD this. need from else So recent – that what of beyond SHIELD will less is fact other we’ll not I initiated surgeons, we the we patients, usually is as see that but start – or in-patient first, partnering investigator But launch, data. be invasive I some what whether initial What of start, the we already II the are we surgeries. would the an more it’s we of But and the for with SHIELD of surgeries into just also their what can scope, data need adoption. look minimally type societies definitely, out-patient research other study, necessarily with the to do, smaller part needed to working II are conversations say kind into else some additional with needed. the trials, for will with which successful expand on into we the clinical

Gary Nachman

great. That’s you. Thank helpful. Okay,

Operator

Thank you.

of comes from the from Please go question ahead. Brandon Folkes Fitzgerald. Cantor Next line

Brandon Folkes

Hi, my congratulations thanks on XX last the years success over all – for Amir, And, question. the taking

Amir Weisberg

you. Thank

Brandon Folkes

you best, taking the forward over all [firmly] [ph]. looking Dikla, to

me of line FDA you detail publicly then questioning. you the going look the the patients trial, think How FDA have at what to enrolled is going secondly, do the expect from XXX? in is Can met of Thank in those it’s earlier the you how sort release you’ve look just additional the assuming think to of you. at data given already do level two patients? positive, just some you do terms you provide analysis? following when along the just maybe And So to of provide you interim

Dikla Czaczkes Akselbrad

low. Well, for additional and made of overwhelming. trial. could Safety There committee expect futility, for but on four to last in that’s are here chances later in. being analysis. give asking Committee including as submission are the will and and additional we the from will the to a DMC to meeting the said, XX% on NDA approval are and part, we terms This you allow so sense that X,XXX the This doing your we that able a you efficacy think the state referring that what are A what this patients, – at needed very of patient do to the effect protection. course, that mean expect you that the is stocks risk for post Monitor I Committee better There patients by investors reduction up I’ll And endpoint is patients? get timelines of us give if – about primary first in ask of more that both always least additional DSMB or be meeting also were we patient is year. And is, the about the precise number the you XXX patients we overall are patients but

Brandon Folkes

of to you. honest kind it, with answered be You

said You sort – of

Dikla Czaczkes Akselbrad

Okay.

Brandon Folkes

futility where my guess I a small case – if question my did just were size, Is that more of kind really like understanding hit right? submit, a it able analysis sort you percentage but is chance know of sample we’re you going sounds to really know that’s correct? like we looks you was that well It accurate the get base to

Dikla Czaczkes Akselbrad

close today’s we and we’re soon, now to we right. – You’re release, very this very expect XXX at said, we it and And patients. we about analysis, in as are

of immediately. going if sense start the the that overall size will from get be to can we’re you – what of this trial So

Brandon Folkes

questions. my you answered Okay. And

very So much. thank you

Dikla Czaczkes Akselbrad

you. Thank

Operator

Thank you.

from question the go Next comes of Buchanan from ahead. JMP Securities. line Please Roy

Roy Buchanan

includes taking sure on trial? tranche, questions. interim. Hi, I had thanks loan facility the $X.X also the – to a that positive for just first million want quick one the the for make I definition upsizing next

Dikla Czaczkes Akselbrad

question, the repeat you please? can Sorry,

Roy Buchanan

The that positive to the enable the the million loan facility tranche trial? from outcome $X.X upsizing includes

Dikla Czaczkes Akselbrad

Yes. To some degree, yes.

Roy Buchanan

Yes.

Dikla Czaczkes Akselbrad

It does.

Roy Buchanan

know then know we but And it. maybe get I motivate really is, D-PLEXXXX the that question to to you going you guess, for for the main Ori, use surgeon great. Okay, what’s

infections. the you you can research to benefit. to know presented it have product something they ethical know the you motivation You obligation from about also is get clear surgeon have penalties a the And hospital’s the if market else But that you’re the quote you giving the shows and about. an think use and data,

So guess product? go into convince the you surgeon going can to bit little you’re Thank a about detail you. I how themselves use to maybe this

Ori Warshavsky

sure. Yeah,

it’s – SSI reduction in easier of So our rate. know the significant it’s you the know straightforward of compared conversation today benchmark a the say I really because the knows other one all, surgeons, that first we, – surgeon that this in would shows every department more their conversation. doctors, departments conversations rate. what They nothing to other know honestly, and their And hospitals do. exists They SSI. with

now, So doctors going show we’re a the to show another right and kind when we we of reduction, get it. research XX% when

package, now of So it. there’s question all full a It’s questions a costs of and there’s honestly between of the pharma economics.

We use data. will

data of Phase amount X. from enormous an really collecting are the We

XXX-plus one recent been the bigger have trials decades. imagine, If that you trial. done a is colorectal the sized of can This in

were right and have beyond a And Dikla quite doctor’s to XX% now, we like there’s are conversation straightforward management doctors management pretty even a and earlier, data time, the So conversation lot at we and of wound of and patient outcomes, – of what interested. can testing really here, reduction mentioning to of questions conferences what a we care. we’re hear to are doctor’s was do

that are complete – sense mentioned their conversation their Member know us bonus the you a – that reduction the is that. of be data that. a measured to I we entire collecting And. measured Board hospital-acquired CEO a of So of and and infections. with the a goals the one that from IDN, can from is which course, of annual had tell Jersey, the pharma you in IDNs New and top of management part bigger of driver on he it’s big last of economics, week I we’re will around really of

So, a of overall hospital. top driver the yes, advantage patient, from to down big there’s expect we’ll from of there’s the also management, but we the take from and driver a the administration big see

Operator

to over speakers back you. to for Thank hand I the would final remarks. like

Dikla Czaczkes Akselbrad

call. members for for next progress external lay our as of program how you their towards of and about speaking our first to-date, partners you forward look in would all We we and the advance that to excited our continuing call. quarter especially well like as conference joining reiterate as to team achieving opportunities as the earnings we providers have our to are D-PLEXXXX clinical goal support commitment, remain to to D-PLEXXXX with quickly and bringing achieved on patients our their our our of We to grateful ahead Thank I in us. possible. healthcare mission

Operator

That today. participating. does conference for conclude you our Thank

You disconnect. all may

PolyPid (PYPD) 11 May 222022 Q1 Earnings call transcript